Aug. 25, 2025 -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced it has secured a $11.25 million extension to its Series B financing. The Series B extension investors include Eshelman Ventures, Eli Lilly and Company, Pharmacosmos and new investor Cape Fear BioCapital. The additional financing will advance Incyclix’s ongoing INX-315-01 (NCT0573508

New hope for millions of glaucoma patients as funding advances surgical access to the uveoscleral pathway Aug. 20, 2025 -- Iantrek, Inc., a pioneer in bio-interventional ophthalmic surgery (BIOS), today announced the close of a $42 million Series C financing round, which will fund the U.S. commercial launch of AlloFlo™ Uveo, a first-of-its-kind surgical solution targeting the uveoscleral pathway, as well as broader pipeline expansion. The Series C was led by U.S. Venture Partners (USVP), joi

Aug. 19, 2025 -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that it has been awarded a $3 million Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). The award evaluates Trethera’s lead candidate, TRE-515, for the treatment of systemic lupus erythematosus (SLE, or ‘lupus’)—a chronic and debilitating autoimmune disease. Trethera wi

Aug. 14, 2025 -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock, par value $0.001 per share, at a price of $4.00 per share. The offering is expected to yield approximately $4 million in gross proceeds before offering expenses and underwriting disco

Aug. 15, 2025 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders’ equity of $3 million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”), as of June 30, 2025. The Equity Rule requires listed companies to maintain a minimum of $2.5 million in stockholders’ eq

Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis August 12, 2025 – Endure Biotherapeutics, Inc. (Endure Bio®), a pioneer in engineered engraftable microbial therapeutics, today announced it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). The funding will support the development of a novel Engineer

Aug. 12, 2025 -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, announced today that it has commenced purchases of Ethereum (ETH), advancing its digital asset treasury reserve strategy. Pursuant to its financing facility of up to $300 million (the “Facility”) with a U.S.-based institutional investor, Cosmos Health has completed its initial $1 million purchase of ETH. Greg Siokas, CEO of Cosmos Health, stated:

Aug. 07, 2025 -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu thereof, with each pre-funded unit cons

$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand $55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and Ligand Proceeds extend expected cash runway into the second half of 2027 and expected to fund completion of enrollment and follow up for the primary endpoint of the BACKBEAT study, as well as substantial enrollment of the Virtue Trial Aug. 05, 2025 -- Orchestra Bi

• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease • Agreement links the organizations’ next-generation proteomics technology and neuroscience leadership to potentially unlock breakthrough therapeutics and biomarkers for neurodegenerative disease July 30, 2025 -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering single-molecule proteome analysis, today